Center for Precision Medicine Research, Marshfield Clinic Research Institute, 1000 N Oak Avenue # MLR, Marshfield, WI, 54449, USA.
Department of Pediatrics, Albert Einstein Medical College, New York, United States.
Sci Rep. 2023 Sep 27;13(1):16269. doi: 10.1038/s41598-023-43217-4.
Multiple sclerosis (MS) is a complex autoimmune disease in which both the roles of genetic susceptibility and environmental/microbial factors have been investigated. More than 200 genetic susceptibility variants have been identified along with the dysbiosis of gut microbiota, both independently have been shown to be associated with MS. We hypothesize that MS patients harboring genetic susceptibility variants along with gut microbiome dysbiosis are at a greater risk of exhibiting the disease. We investigated the genetic risk score for MS in conjunction with gut microbiota in the same cohort of 117 relapsing remitting MS (RRMS) and 26 healthy controls. DNA samples were genotyped using Illumina's Infinium Immuno array-24 v2 chip followed by calculating genetic risk score and the microbiota was determined by sequencing the V4 hypervariable region of the 16S rRNA gene. We identified two clusters of MS patients, Cluster A and B, both having a higher genetic risk score than the control group. However, the MS cases in cluster B not only had a higher genetic risk score but also showed a distinct gut microbiome than that of cluster A. Interestingly, cluster A which included both healthy control and MS cases had similar gut microbiome composition. This could be due to (i) the non-active state of the disease in that group of MS patients at the time of fecal sample collection and/or (ii) the restoration of the gut microbiome post disease modifying therapy to treat the MS. Our study showed that there seems to be an association between genetic risk score and gut microbiome dysbiosis in triggering the disease in a small cohort of MS patients. The MS Cluster A who have a higher genetic risk score but microbiome profile similar to that of healthy controls could be due to the remitting phase of the disease or due to the effect of disease modifying therapies.
多发性硬化症(MS)是一种复杂的自身免疫性疾病,其中遗传易感性和环境/微生物因素的作用都已得到研究。已经确定了 200 多种遗传易感性变异,以及肠道微生物组的失调,这两者都独立地与 MS 相关。我们假设,携带遗传易感性变异和肠道微生物组失调的 MS 患者发生该疾病的风险更高。我们在同一组 117 例复发缓解型多发性硬化症(RRMS)和 26 例健康对照者中,调查了 MS 的遗传风险评分与肠道微生物组之间的关系。使用 Illumina 的 Infinium Immuno array-24 v2 芯片对 DNA 样本进行基因分型,然后计算遗传风险评分,通过测序 16S rRNA 基因的 V4 高变区来确定微生物组。我们确定了两组 MS 患者,A 组和 B 组,它们的遗传风险评分均高于对照组。然而,B 组的 MS 病例不仅遗传风险评分更高,而且肠道微生物组也与 A 组明显不同。有趣的是,包括健康对照和 MS 病例的 A 组具有相似的肠道微生物组组成。这可能是由于(i)在粪便样本采集时,该组 MS 患者疾病处于非活动状态,和/或(ii)疾病修饰疗法治疗 MS 后,肠道微生物组得以恢复。我们的研究表明,在一小部分 MS 患者中,遗传风险评分和肠道微生物组失调之间似乎存在关联,从而引发疾病。具有更高遗传风险评分但微生物组谱与健康对照组相似的 MS A 组可能是由于疾病的缓解期,或是由于疾病修饰疗法的影响。